Alice Melão,  —

Continuous monitoring of movement symptoms using a wearable device called the Personal KinetiGraph (PKG) may help clinicians make more appropriate treatment choices for their patients with Parkinson’s disease, according to a real-world clinical study. The study, “Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a…

Neurocrine Biosciences and Voyager Therapeutics have joined efforts in a new strategic collaboration to further develop and market Voyager’s gene therapies VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia. With this partnership, Neurocrine Biosciences will apply its expertise in neuroscience, drug development, and…

Biogen and C4 Therapeutics (C4T) have joined efforts to develop therapies using a cell’s natural protein degradation system as a way of treating neurological diseases such as Alzheimer’s and Parkinson’s. This agreement allows the two to combine Biogen’s expertise in neuroscience and therapy development with C4T’s…

Parkinson’s patients show less ability to participate in work life even in the early stages before they are diagnosed with the disease, a study shows. In combination with biochemical and genetic biomarkers, this finding may help identify patients at risk of developing this progressive neurodegenerative disease before motor…

Rodin Therapeutics has started a Phase 1 clinical trial to explore the safety of its synthetic compound, RDN-929, to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, by protecting synapses. The trial (NCT03668314), is designed to assess the safety, tolerability, pharmacokinetics — how the body affects a medicine…

Voyager Therapeutics has begun patient dosing in a Phase 2 trial testing its investigational VY-AADC gene therapy in Parkinson’s patients whose motor symptoms are not responding adequately to oral medication. The trial, called RESTORE-1 (NCT03562494), is recruiting participants across seven sites in the United States. VY-AADC is a therapy that delivers…

Older patients with inflammatory bowel disease (IBD) are more likely to develop Parkinson’s disease than those without the condition, a meta-analysis suggests. Whether the same association exists for younger patients — ages 59 or younger — remains to be determined, according to the researchers. The study, “Older…

Impaired sense of smell or taste can raise a person’s risk of developing Parkinson’s disease 2.5 times, a study suggests. The study, “Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss,” was published in the Journal of Neurology. Currently, Parkinson’s…

Essential oil extract from the leaves of a Brazilian plant can protect nerve cells from damage and prevent progressive physical impairment in a mouse model of Parkinson’s disease, a study shows. The study, “Eplingiella fruticosa leaf essential oil complexed with…

Mission Therapeutics and AbbVie have established a new partnership aimed at developing specific inhibitors targeting deubiquitylating enzymes, or DUBs, for the treatment of Alzheimer’s and Parkinson’s diseases. DUBs are a large family of important enzymes that regulate the protein degradation process, some of which are involved in the…